Front Row Advisors LLC Arbutus Biopharma Corp Transaction History
Front Row Advisors LLC
- $277 Million
- Q4 2024
A detailed history of Front Row Advisors LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Front Row Advisors LLC holds 10,500 shares of ABUS stock, worth $36,225. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$36,225
Previous $40,000
15.0%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
165Shares Held
102MCall Options Held
649KPut Options Held
666K-
Morgan Stanley New York, NY22.6MShares$77.9 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$45.7 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.98MShares$31 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$30.2 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $517M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...